

10th
National
Congress of
EM
&
1st
Intercontinental
EM Congress



1

Renal Transplantation Patient in ER

Mehmet ERGİN; MD, EP, Assist. Prof.

Near East University Medicine School Emerg Dep / Lefkoşa

Turkish Republic of North Cyprus

Principles

2

□ Transplanted organs

- are devoid of their native innervations.
- have surgical anastomoses

▣ Pain ?

▣ Inflammatory and immunologic response to infection and malignancy?

- Subtle signs and symptoms...

Principles

3

- Anatomic relationships
 - To anticipate leakages & blockages of vital anastomoses

- Baseline physiological capacity of allograft
 - ...small changes in the baseline functional level ?

Principles

4

- Transplant organ complications
 - Anatomy
 - Infection
 - Rejection
 - Drug toxicity
- The exact etiology is not determined until admission to hospital!
- Time since transplant!

5 Transplantation Techniques

Transplantation Techniques

6

Early Complications

- General
 - Wall Abscesses, Hemorrhage, Hematuria, Incisional Hernia
- Urinary Fistula
- Arterial Thrombosis
- Venous Thrombosis

Late Complications

- Ureteral Stenosis
- Reflux and acute pyelonephritis
- Kidney Stones
- Renal Artery Stenosis
- Arteriovenous Fistula and Pseudo-aneurysms After Renal Biopsy
- Lymphocele

Transplantation Techniques

7

Early Complications

General: Wall
Abscesses,
Hemorrhage,
Hematuria,
Incisional Hernia

Urinary Fistula

Arterial
Thrombosis

Venous
Thrombosis

- During immediate and early post-operative process
- Management
 - Drainage of abscess or hematoma
 - Ureteral stenting
 - Percutaneous nephrostomy
 - Hernia repair
 - Vesical catheter and/or double J-stent
 - Radiological or surgical thrombectomy
 - Transplantectomy

Transplantation Techniques

8

Late Complications

- ① Ureteral Stenosis
 - the dilated renal calyces and pelvis
 - often an elevated creatinine level
 - in 5% (range, 2-7.5%) of transplants
 - present late between 1 and 10 years' post transplant.

Transplantation Techniques

9

Late
Complications

Ureteral
Stenosis

- Three causes of ureteral dilatation
 - Vesical high pressure in thickened bladder wall or urinary retention
 - Vesicorenal reflux
 - Ureterovesical reflux due to scar formation and/or poor surgical technique
 - 80% of uretral stenosis
 - Most during the first year post transplant

Transplantation Techniques

10

Late
Complications

Ureteral
Stenosis

□ Management

- Initial treatment; percutaneous drainage and checking renal function to see if it has improved.
- Further treatment according to the level of stenosis, degree and delay of occurrence.
 - Endoscopic, either transurethral or percutaneous intervention
 - Open surgery

Transplantation Techniques

11

Late Complications

- ② Reflux and acute pyelonephritis
 - Acute pyelonephritis is rare
 - Reflux in the renal cavity is more common
 - In lower urinary tract infections, the risk of acute pyelonephritis is 80% with reflux and 10% without reflux
 - Every reflux complicated by acute pyelonephritis
 - should be treated with an endoscopic injection.
 - If fails, uretero-ureteral anastomosis or an ureterovesical re-implantation...

Transplantation Techniques

12

Late Complications

③ Kidney Stones

- be transplanted with the kidney or acquired.
- <1% of transplants.
- Hematuria, infection or obstruction.
- Non-contrast CT scan.

Transplantation Techniques

13

Late
Complications
Kidney Stones

□ Management

- Double J catheter or echo-guided percutaneous nephrostomy*
- Extracorporeal Shock Wave Lithotripsy (ESWL)
- Percutaneous or open nephrolithotomy.
- Ureteroscopy

Transplantation Techniques

14

Late Complications

- ④ Renal Artery Stenosis
 - In 10% (range, 2-38%) of transplants
 - should be suspected when
 - existing arterial hypertension becomes refractory to medical treatment **and/or**
 - an increase in serum creatinine without hydronephrosis.
 - Doppler Sonography
 - showing high velocity $> 2\text{m/s}$.

Transplantation Techniques

15

Late
Complications

Renal Artery
Stenosis

□ Management

- Medical treatment and renal function follow-up
- Interventional treatment if the stenosis is $> 70\%$
 - Transluminal dilatations, with or without stenting,
 - the first-line treatment for aligned and distal stenosis.
 - Open surgery
 - in case of plication or anastomotic stenosis, failure of percutaneous dilatation

Transplantation Techniques

16

Late Complications

- ⑤ Arteriovenous fistula and pseudo aneurysms after renal biopsy
 - in 10% (range, 7-17%) of transplants
 - Repeated haematuria.
 - Doppler USG & confirmation by MRI or angiography.
 - Management
 - Angiography is also the first step in treatment.
 - Selective embolization
- ▣ Pseudo aneurysms are often due to mycotic infection and can be fatal.

Transplantation Techniques

17

Late Complications

⑥ Lymphocele

- 1-20% of complications.
- Generally asymptomatic, but may be pain due to ureter compression or infection.
- Management
 - No treatment for mild lymphocele or if no compression of the iliac vessels or the transplant ureter.
 - Laparoscopic marsupialisation OR open surgery

18

Immunosuppression

Immunosuppression

19

- Principle of 'the balance of survival'.
 - a dosage of drug high enough to suppress rejection without endangering the recipient's health.

- Safe modern immunosuppressive agents
 - suppress sensitized lymphocyte activity against a transplant.

Immunosuppression

20

□ Drugs

▣ Calcineurin inhibitors

- Cyclosporine, tacrolimus

▣ Antimetabolites

- Mycophenolate
 - MMF or enteric-coated mycophenolate sodium, EC-MPS
- Azathioprine

▣ Steroids

- Prednisolone or methylprednisolone

▣ With or without induction therapy

Dose-dependent side effects

21

□ Calcineurin inhibitors

- Nephrotoxic, hypercholesterolemia, hypertension, gum hypertrophy, constipation, hirsutism and acne diabetes, neurological and gastro-intestinal side-effects, polyoma nephritis

□ Antimetabolites

- Inhibition of bone marrow function, gastrointestinal side-effects, polyoma nephritis

Non-specific side-effects of immunosuppression

22

- A higher risk of
 - ▣ Malignancy
 - ▣ Infection
 - particularly opportunistic infections

Non-specific side-effects of immunosuppression

23

Infection

- Primary cause of mortality after transplantation
- Signs - often blunted
- Aggressive management
- Primary sources
 - Pretransplant, community acquired, transmission from organ donor and nosocomial.
- Vaccines with live viral antigens shouldn't be!

Non-specific side-effects of immunosuppression

24

Infection

- First month post transplant
- Between 1 to 6 month
- More than 6 month

Non-specific side-effects of immunosuppression

25

Infection

First Month
After
Transplant

- Related to the transplant procedure, catheters and intubation.
- The typical causes of postoperative fever must be considered!
- Management
 - Similar to that for any immunosuppressed patient

Non-specific side-effects of immunosuppression

26

Infection

1 to 6 Months
After
Transplant

□ Immunomodulating viral infections

- Cytomegalovirus (CMV)
- Hepatitis B and C
- BK Polymavirus
- Human Herpes Virus 6
- Epstein-Barr Virus (EBV)

□ Opportunistic infections

- Pneumocytis
- Listeria
- Fungal

Non-specific side-effects of immunosuppression

27

Infection

1 to 6 Months
After
Transplant

□ CMV

- produce multisystem disease
 - Pneumonitis – particularly common
 - Typically, signs at 40 days after transplant
- Early diagnosis with bronchoscopy
- Aggressive treatment with gancyclovir and CMV-specific immunoglobulin
- Active infection trigger or exacerbate organ rejection!

Non-specific side-effects of immunosuppression

28

Infection

1 to 6 Months
After
Transplant

□ EBV

- Similar clinical effects as CMV
- Often coexistence with CMV

▣ Mononucleosis like syndrome

- Lymphadenopathy, weakness, low-grade fever

▣ B cell lymphoproliferative syndrome

Non-specific side-effects of immunosuppression

29

Infection

6 Months
After
Transplant

- ☐ Healthy Transplant
- ☐ Chronic Viral Infection
- ☐ Chronic Rejection

Non-specific side-effects of immunosuppression

30

Infection

6 Months
After
Transplant

□ Healthy Transplant

- No chronic immunomodulating viral infection
- Mildly-increased susceptibility to normal community-acquired infections

Non-specific side-effects of immunosuppression

31

Infection

6 Months
After
Transplant

□ Chronic Viral Infection

- Progressive liver disease
 - due to recurrent or acquired viral hepatitis
- B cell lymphoproliferative disorders
 - Associated with EBV
- Primary Varicella Infection
- Reactivation of latent VZV infection
- HSV reactivation

Non-specific side-effects of immunosuppression

32

Infection

6 Months
After
Transplant

□ Chronic Rejection

- In need of aggressive immunosuppressive tx
 - High risk of life threatening opportunistic infections with
 - Fungi
Candida, Cryptococcus, Coccidioides, Blastomyces, Histoplasma
 - Bacteria
Listeria, Nocardia
 - Parasites
Pneumocystitis, Toxoplasma, Strongyloides

IMMUNOLOGICAL COMPLICATIONS

Determining factors in rejection episodes and response to treatment

34

- Degree of sensitization to HLA
- Degree of HLA-mismatch, particularly in sensitized recipients
- History of previous episodes
- Previous transplantations, especially when graft loss has occurred due to acute rejection
- Non-compliance with immunosuppressive treatment
- Some virus infections, e.g. CMV

Immunological Complications

35

Main types of rejection

- ❑ Hyper acute rejection (HAR)
- ❑ Acute allograft rejection
 - ▣ Acute cellular rejection (ACR)
 - ▣ Acute humoral Rejection (AHR)
- ❑ Chronic allograft rejection (CAR)

Hyper Acute Rejection (HAR)

36

- Antibody-mediated rejection is caused by pre-formed anti-HLA or anti-AB (Blood group) antibodies
- Rare due to donor-recipient ABO matching and routine pre-transplant cross-matching between donor cells and recipient serum

Acute Allograft Rejection

37

Acute Cellular Rejection (ACR)

- ❑ Much more than common than HAR, occurring in 10-40% of transplants
- ❑ Usually occurs from 5 days' post transplant
- ❑ Most likely within 3 months, though may occur after this time
- ❑ Usually responds well to steroid bolus treatment

Acute Humoral Rejection (AHR)

- ❑ Much less frequent than HAR, occurring in 5-20% of transplants
- ❑ Most likely within 3 months' post transplant
- ❑ Presence of certain histological features and/or C4d immunostaining and/or anti-HLA antibodies
- ❑ Worse prognosis than ACR since more difficult to treat

Chronic Allograft Rejection

38

- Rare, slowly progressive, immunological process
- Certain non-specific histological features and/or anti-HLA antibodies
- Requires clear strong evidence for a solely chronic immunological process

Differential diagnosis for rejection

39

- Transplant biopsy
 - ▣ The gold standard for the diagnosis of ACR, AHR and CAR!
 - ▣ demonstrate a mixed histological picture in many cases.
 - The Banff criteria
 - uniform criteria applied to biopsy
 - the basis for deciding prognosis and treatment

Take home messages

40

Clinical Features

- Allograft rejection symptoms are usually unclear and non-specific.
- The signs and symptoms of infectious complications depend on
 - the nature of pathogenic organism
 - location of infection
 - level of immunosuppression
- Careful attention to maintain appropriate level of immunosuppression and watching for the typical transplant-related complications.

Take home messages

41

Diagnostic Features

- ❑ Transplant patient must undergo extensive laboratory and radiographic evaluation
 - ▣ To rule out myriad infectious etiologies
 - ▣ To assess allograft function
 - ▣ To survey for signs of drug toxicity

Take home messages

42

Laboratory assessment

- ❑ Organ-specific measures of function
- ❑ Evidence of infection

Radiologic assessment

- ❑ Sources of infection
- ❑ Relevant anatomy of the patient's allograft

FURTHER READINGS...

43

- ❑ Guidelines on Renal Transplantation 2010. European Association of Urology
- ❑ Clinical practice guidelines. Post-operative Care of the Kidney Transplant Recipient. UK Renal Association 5th Edition Final Version (5th February 2011)
- ❑ Keadey MT. The Solid Organ Transplant Patient. In Marx JA, Editor. Rosen's Emergency Medicine Concepts and Clinical Practice. 7th ed. Philadelphia: Mosby Elsevier; 2010. pp.2365-74

10th
National
Congress of EM
&
1st
Intercontinental
EM Congress



44

Soma / Manisa...

Thanks for listening
drmehmetergin@gmail.com